Raymond James AnalystOne needs to consider that our one sole analyst from Raymond James has been waiting for the release of independent third party review report on phase 2 trial.
Now we know Health Canada has seen data as they approved a phase 3 Catco Trial which never was completed do to lack of patients.
We know that FDA has seen data and approved new phase 2 AKI trial.
The Canadian government recently gave $5M to Arch for producing/manufacturing the drug for future trials thus eliminating the need to raise capital and shareholder dilution
The above is all extremely positive and bullish yet the markets fail to acknowledge or react to.
Now here is the icing on the cake. Both the FDA and Health Canada have seen the data and approved new trials based on that data, hence one could conclude the data is positive and the 3rd party independent review will indicate that.
This should please the analyst at Raymond James and cause him to raise his target prices, derisk the science. For those who do not know what kind of weight Raymond James has, well consider this. Raymond James manages $1.3 trillion dollars so a positive upgrade from their analyst could spur the buying we need to drive this higher.